PEAR - Pear Therapeutics Spero expand partnership for digital therapeutics for substance use

January, 04 2023 08:45 AM Pear Therapeutics Inc.

Pear Therapeutics ( NASDAQ: PEAR ) and Spero Health have extended a partnership for the former to provide the latter prescription digital therapeutics for the treatment of substance use and opioid use disorders.
Shares are up 4% in premarket trading.
The extended arrangement will allow eligible Spero patients in 99 locations to the reSET and reSET-O programs for each condition.
Both programs utilize cognitive behavioral therapy as a adjunct to outpatient treatment.
Spero has already implemented the programs at 14 locations in Kentucky.
Ready why Seeking Alpha contributor Valkyrie Trading Society rates Pear ( PEAR ) a buy.

For further details see: